Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 11, 2019 at 10:12 AM.

  1. #1 cafead, Jul 11, 2019 at 10:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,962
    Likes Received:
    3
    via San Diego-based Mirati Therapeutics and Swiss pharma giant Novartis have teamed up to evaluate the combination of an investigational KRAS G12C inhibitor and an investigational SHP2 inhibitor in patients with advanced solid tumors that harbor KRAS G12C mutations.

    article source
     
    Quote

  2. #2 VINU ANALYST, Dec 31, 2019 at 7:44 AM
    VINU ANALYST

    VINU ANALYST Guest

    Great news for Mirati. This will help them to compete stongly with Amgen. Do you know the status of the combination trial? When they are going to start it?
     
    Quote
  3. #3 VINU ANALYST, Jan 7, 2020 at 1:35 AM
    VINU ANALYST

    VINU ANALYST Guest

    Some clinical locations are struggling to get the MRTX849 for the trials & have difficulties to continue the trial. Is this a rumour?
     
    Quote
Reply to Thread